idecabtagene vicleucel

Idecabtagene vicleucel is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell therapy. It is an autologous cell therapy, meaning it is manufactured from a patient’s own T cells, which are genetically modified to express a CAR targeting BCMA, a protein highly expressed on multiple myeloma cells. Upon reinfusion into the patient, these engineered T cells recognize and eliminate BCMA-expressing myeloma cells. Idecabtagene vicleucel has demonstrated significant efficacy in adults with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody[1][2][4][5]. The drug has shown high overall response rates and durable responses in heavily pretreated patients.

Brand names

Abecma

Other names

伊基奥仑赛